Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia

QJM: An International Journal of Medicine

Volumn 92, Issue 8, 1999, Pages 433-441

  BjOro K ^a   Skaug, K ^a   Haaland, T ^a   FrOland S S ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; HYPOGAMMAGLOBULINEMIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0032868251     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/92.8.433     Document Type: Article

References (31)

1. Lever AML, Brown D, Webster ADB, Thomas HC. Non-A, non-B hepatitis occurring in agammaglobulinemic patients after intravenous immunoglobulin. Lancet 1984; 2:1062-4.
2. Björkander J, Cunningham-Rundles C, Lundin P, Olsson R, Söderström R, Hanson LA. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinaemia or IgC subclass deficiency. Am J Med 1988; 84:107-11.
3. Bjøro K, Frøland SS, Yun Z, Samdal H, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331:1607-11.
4. Healey CJ, Sabharval NK, Daub J, Davidson F, Yap PL, Fleming KA, Chapman RWG, et al. Outbreak of acute hepatitis C following the use of anti-hepatitis virus screened intravenous immunoglobulin therapy. Gastroenterology 1996; 110:1120-6.
5. Seef LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, et al. Long-term mortality after transfusion associated non-A, non-B hepatitis. N Engl J Med 1992; 327:1906-11.
6. Sanches-Tapias JM, Barrera JM, Costa J, Ercilla MG, Pares A, Comalrrena L, Soley F, et al. Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med 1990; 112:921-4.
7. Rossi G, Tucci A, Cariani E, Ravaggi A, Rossini A, Radaeli E. Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status. Blood 1997; 90:1309-14.
8. Munoz FJ, de la Calle A, Gimenez MJ, Gonzalez J, Conde J. Unusual course of the hepatitis C virus infection in one patient diagnosed of common variable immundeficiency. Allergol Immunopathol 1995; 23:263-6.
9. Christie IML, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N, Rosenberg WMC, et al. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis: 2 year follow-up. Clin Exp Immunol 1997; 110:4-8.
10. Quinti I, Pandolfi F, Paganelli R, El Salman D, Giovannetti A, Rosso R, Oliva A, et al. HCV infection in patients with primary defects of immunoglobulin production. Clin Exp Immunol 1995; 102:11-16.
11. Quinti I, Pandolfi F, Paganelli R, Giovannetti A, Sacco G, Oliva A, Aiuti F. Hepatitis C virus infection in Italian patients with hypogammaglobulinaemia. Clin Ther 1996; 18 Suppl B:96-107.
12. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-32.
13. McHutchinson J, Gordon S, Schiff E, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-92.
14. Spickett GP, Misbah SA, Chapel HM. Primary antibody deficiency in adults. Lancet 1991; 337:281-4.
15. WHO. Primary immunodeficiency disease: Report of a WHO scientific group. Clin Exp Immunol 1997; Suppl 1:1-28.
16. Aukrust P, Frøland SF, Müller F. Raised serum neopterin levels in patients with primary hypogammaglobulinaemia: correlation to other immunological parameters and to clinical and histological features. Clin Exp Immunol 1992; 89:211-16.
17. Muerhoff AS, Simons JN, Erker JC, Desai SM, Mushawar IK. Identification of conserved nucleotide sequences within the GB virus 5′ untranslated region: design of PCR primers for detection of viral RNA. J Virol Method 1996; 62:55-62.
18. Tremolada F, Casparin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G. Long-term follow-up of NANB (type C) post-transfusion hepatitis. J Hepatol 1995; 16:273-81.
19. Wies M. Natural course of hepatitis C: 15-year analysis in an unselected group with identical parenteral infection. J Hepatol 1995; 23:89-94.
20. Poynard T, Bedossa P, Opolon P. Natural history of fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-32.
21. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated hepatitis C virus related cirrhosis. Gastroenterology 1997; 1112:463-72.
22. Bjøro K, Frøland SF, Skaug K, Haaland T. The spectrum of hepatobiliary diseases in primary hypogammaglobulinemia. J Intern Med 1999; 245:517-24.
23. Roudot-Thoraval F, Bastie A, Pawltosky JM, Dhumeaux D and the Study Group for the Prevalence and the Epidemiology of Hepatitis C virus. Epidemiological factors affecting the severity of hepatitis C virus related disease: a French survey of 6664 patients. Hepatology 1997; 26:485-90.
24. Morris A, Webster ADB, Brown D, Harrison TJ, Dusheiko G. GB virus C infection in patients with primary antibody deficiency. J Infect Dis 1998; 177:1719-22.
25. Mechanic LJ, Diknian S, Cunningham-Rundles C. Granulomatous disease in common variable immundeficiency. Ann Intern Med 1997; 127:613-17.
26. Mellors JW, Munoz A, Giorig JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV infection. Ann Intern Med 1997; 126:946-54.
27. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4 + lymphocyte counts predict both response to antiviral therapy and therapeutic failure. Ann Intern Med 1997; 126:939-45.
28. Fox JC, Kidd IM, Griffiths PD, Sweny P, Emery VC. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: Correlation with disease. J Gen Virol 1995; 76:306-19.
29. Cope AV, Sweny P, Sabin C, Rees L, Griffiths PD, Emery VC. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 1997; 52:200-5.
30. Booth JCL, Foster GR, Kumar U, Calassini R, Goldin RD, Brown JL, Thomas HC. Chronic hepatitis C virus infections: predictive value of genotype and level of viremia on disease progression and response to interferon. Gut 1995; 36:427-32.
31. Serfaty L, Aumaitre H, Chazouilleres O, Bonnard AM, Rosmarduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis virus-related cirrhosis. Hepatology 1998; 27:1435-40.